Related Experiment Videos
CYP2D6-related oxidation polymorphism in Italy
E Spina1, G M Campo, A Avenoso
1Institute of Pharmacology, School of Medicine, University of Messina, Italy.
Pharmacological Research
|April 1, 1994
Summary
This study investigated the cytochrome CYP2D6 (debrisoquine type) oxidation polymorphism in 246 Italian volunteers. We found that 4.5% of the population are poor metabolizers, consistent with other Caucasian groups.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Clinical Chemistry
Background:
- Cytochrome P450 enzymes, particularly CYP2D6, play a crucial role in drug metabolism.
- Genetic variations in CYP2D6 lead to significant interindividual differences in drug response.
- Understanding the distribution of CYP2D6 polymorphisms is essential for personalized medicine.
Purpose of the Study:
- To determine the allelic frequency of CYP2D6 oxidation polymorphism in a healthy Italian population.
- To phenotype CYP2D6 metabolic activity using dextromethorphan as a probe drug.
- To establish the prevalence of poor metabolizer phenotype in this cohort.
Main Methods:
- Phenotyping 246 healthy Italian volunteers using dextromethorphan hydrobromide.
- Quantifying dextromethorphan and dextrorphan in urine via High-Performance Liquid Chromatography (HPLC).
- Calculating the metabolic ratio (MR) to assess CYP2D6 activity.
Main Results:
- Significant interindividual variability in dextromethorphan urinary excretion (0.04-3.9%) and metabolic ratios (0.001-6.6).
- Eleven subjects (4.5%) exhibited a metabolic ratio > 0.30, classifying them as poor metabolizers.
- The observed frequency of poor metabolizers aligns with previously reported data for Caucasian populations.
Conclusions:
- The prevalence of CYP2D6 poor metabolizer phenotype in Italians is approximately 4.5%.
- This finding supports the importance of considering CYP2D6 genetic variability in drug therapy within this population.
- Further research can explore the clinical implications of this polymorphism in Italian patients.